First Time Loading...

Arcus Biosciences Inc
NYSE:RCUS

Watchlist Manager
Arcus Biosciences Inc Logo
Arcus Biosciences Inc
NYSE:RCUS
Watchlist
Price: 18.88 USD 3.68% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

RCUS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. [ Read More ]

The intrinsic value of one RCUS stock under the Base Case scenario is 14.3 USD. Compared to the current market price of 18.88 USD, Arcus Biosciences Inc is Overvalued by 24%.

Key Points:
RCUS Intrinsic Value
Base Case
14.3 USD
Overvaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Arcus Biosciences Inc

Backtest RCUS Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RCUS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Strong Prospects for HIF2-alpha Program
2023-Q4 Earnings Call

Strong Prospects for HIF2-alpha Program

The company sees their HIF2-alpha inhibitor as a major opportunity, suggesting its potential for significance within the pharmaceutical landscape akin to Merck's blockbuster. They believe their molecule has a competitive advantage as they can pursue fivefold higher dosages, leading to greater efficacy without indications of increased toxicity. Furthermore, their PK/PD profile shows promise, and no dose-limiting toxicities (DLTs) have been observed. The company will continue to evaluate their pipeline, including the discontinued ARC-10 trial, and decide on the strategic direction based on data maturity and impact on ongoing studies.

Financials

Balance Sheet Decomposition
Arcus Biosciences Inc

Current Assets 831m
Cash & Short-Term Investments 759m
Receivables 42m
Other Current Assets 30m
Non-Current Assets 264m
Long-Term Investments 107m
PP&E 143m
Other Non-Current Assets 14m
Current Liabilities 184m
Accounts Payable 17m
Accrued Liabilities 76m
Other Current Liabilities 91m
Non-Current Liabilities 449m
Other Non-Current Liabilities 449m
Efficiency

Earnings Waterfall
Arcus Biosciences Inc

Revenue
117m USD
Operating Expenses
-457m USD
Operating Income
-340m USD
Other Expenses
33m USD
Net Income
-307m USD

Free Cash Flow Analysis
Arcus Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

RCUS Profitability Score
Profitability Due Diligence

Arcus Biosciences Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
21/100
Profitability
Score

Arcus Biosciences Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

RCUS Solvency Score
Solvency Due Diligence

Arcus Biosciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
55/100
Solvency
Score

Arcus Biosciences Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RCUS Price Targets Summary
Arcus Biosciences Inc

Wall Street analysts forecast RCUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RCUS is 39.98 USD with a low forecast of 24.24 USD and a high forecast of 73.5 USD.

Lowest
Price Target
24.24 USD
28% Upside
Average
Price Target
39.98 USD
112% Upside
Highest
Price Target
73.5 USD
289% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RCUS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RCUS Price
Arcus Biosciences Inc

1M 1M
-1%
6M 6M
+5%
1Y 1Y
+5%
3Y 3Y
-35%
5Y 5Y
+51%
10Y 10Y
+11%
Annual Price Range
18.88
52w Low
13.43
52w High
23.54
Price Metrics
Average Annual Return 38.11%
Standard Deviation of Annual Returns 96.99%
Max Drawdown -72%
Shares Statistics
Market Capitalization 1.7B USD
Shares Outstanding 90 860 000
Percentage of Shares Shorted 12.69%

RCUS Return Decomposition
Main factors of price return

What is price return decomposition?

RCUS News

Last Important Events
Arcus Biosciences Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Arcus Biosciences Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Arcus Biosciences Inc Logo
Arcus Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.7B USD

Dividend Yield

0%

Description

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 366 full-time employees. The company went IPO on 2018-03-15. The firm's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The firm's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers. Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.

Contact

CALIFORNIA
Hayward
3928 Point Eden Way
+15106946200.0
https://arcusbio.com/

IPO

2018-03-15

Employees

366

Officers

Co-Founder, Chairman & CEO
Dr. Terry J. Rosen Ph.D.
Co- Founder & President
Dr. Juan Carlos Jaen Ph.D.
Principal Financial Officer & CFO
Mr. Robert C. Goeltz II
Chief Operating Officer
Ms. Jennifer A. Jarrett M.B.A.
Chief Medical Officer
Dr. Dimitry S.A. Nuyten M.D., Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. K. Christopher Garcia Ph.D.
Show More
VP of Finance & Principal Accounting Officer
Mr. Alexander Azoy
Chief Scientific Officer
Dr. Jonathan Yingling Ph.D.
Vice President of Investor Relations & Corporate Strategy
Ms. Katherine Bock
General Counsel & Corporate Secretary
Ms. Carolyn C. Tang J.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one RCUS stock?

The intrinsic value of one RCUS stock under the Base Case scenario is 14.3 USD.

Is RCUS stock undervalued or overvalued?

Compared to the current market price of 18.88 USD, Arcus Biosciences Inc is Overvalued by 24%.